Biomolecular Life Holdings, Inc.

Biomolecular Life Holdings, Inc. is a drug discovery and development company focused on two core technologies: Targeted Peptide Technology (TPT) and Metabolic Disruption Technology (MDT). TPT is the company's main focus, with research indicating its potential use in treating autoimmune diseases. Autoimmune diseases occur when the immune system inappropriately targets healthy self-cells, leading to chronic inflammation. Current therapies for these disorders often involve non-specific immunosuppression, which can weaken a patient's ability to fight secondary infections. Biomolecular Life Holdings, Inc. believes it has produced a peptide, a small protein segment, that may selectively eliminate specific pro-inflammatory immune system cells involved in inflammatory and autoimmune conditions. This TPT therapy requires further development, including favorable animal toxicity study results and regulatory approval of protocols, before clinical trials can begin. The company believes TPT could be a significant discovery for patients with largely untreatable autoimmune diseases. MDT is the company's secondary focus, with one drug research program currently in the clinical stage. This MDT therapy is designed to help fight cancers with solid tumors, in combination with other drugs, when the cancer is resistant to initial cancer drug therapy.